Software for
Business Intelligence

BizInt Smart Charts

May I have your Attention?

Maximize the Impact of Your S[illegible]lts

Matt Eberle, Analytics & Custom Solutions

PIUG 2025 Annual Conference

May 2025

www.bizint.co[illegible]


E-MAILS –TODAY AM
LAST WEEK'S EMAIL
EMAILS FOR REVIEW LATER
TOP SECRET
IP SEARCH RESULTS

"There's no point in acting surprised about it. All the planning charts and demolition orders have been on display at your local planning department in Alpha Centauri for 50 of your Earth years, so you've had plenty of time to lodge any formal complaint and it's far too late to start making a fuss about it now."

-Douglas Adams, The Hitchhiker's Guide to the Galaxy


Deliver information that's needed,
when and where it's needed,
in a format that captures and sustains
attention.



"It is conventional to begin…by considering the information [we] will supply. In an information-rich world, however, this is doing things backwards. **The crucial question is how much information [we] will allow to be withheld**"

-Herbert Simon, Designing Organizations for an Information-rich World, 1971


“To be an attention conserver for an organization… be an information condenser.“
Simon, 1971

Or, to put it in Internet lingo...

TL;DR

But, if you do read books..



What's needed for effective summary?



- Condensed
- Compelling
- Focused
- Integrated
- Reliable

 | www.bizint.com

Text can provide a good summary



L6 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2024 ACS on STN
PatentPak PDF | PatentPak PDF+ | PatentPak Interactive
Title
Methods of treating and neurological and mental disorders using oxytocin and neuroplasticity agents
Accession Number
2023:1595125 CAPLUS Full-text
Document Type
Patent
Language
English
Author/Inventor
Belnap, Drew Grant
Patent Assignee/Corporate Source
Belnap Pharmaceuticals, LLC, USA
Ultimate Owner
BELNAP PHARMACEUTICALS LLC
Document Number
183:306661
Family Accession Number Count
1
Source
PCT Int. Appl., 55pp.
CODEN: PIXXD2
PatentPak Patent Information

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2023146579	A1	20230803	English	PDF | PDF+ | Interactive

Text can provide a good summary

13.	**Title:**	**Exploring the hydrophilic and hydrophobic cluster of oxytocin. A pathway leading to antagonistic action**
	Database:	Chemical Abstracts (non-patent)
	Source:	Epitheorese Klinikes Farmakologias kai Farmakokinetikes, International Edition (1995), 9(2 and 3), 99-102 CODEN: EFKEEB; ISSN: 1011-6583
	Inventor(s):	Theodoropoulos, D.; Cordopatis, P.
	Patent Assignee:	Department Chemistry, University Patras, 26 500, Greece
	Abstract:	A systematic effort to relate the proposed three-dimensional structure of the neurohypophyseal hormones oxytocin and vasopressin to their biol. activity has led, from our part, to synthetic analogs with specifically modified activity profiles. These analogs were prepd. either by solid phase synthesis or individual couplings in soln. and resulted fro modifications in the 20-membered ring structure or/and the flexible terminal portion o hormones [CONT.]

14.	**Title:**	**Conformational studies of oxytocin analogs**
	Database:	Chemical Abstracts (non-patent)
	Source:	Polish Journal of Chemistry (1994), 68(5), 987-95 CODEN: PJCHDQ; ISSN: 0137-50
	Inventor(s):	Kasprzykowski, F.; Skurski, P.; Liwo, A.; Lankiewicz, L.; Oldziej, St.; Lanoszka, J.; Wiczk, W.; Grzonka, Z.
	Patent Assignee:	Fac. Chem., Univ. Gdansk, Gdansk, 18 80-952, Pol.
	Abstract:	Oxytocin (OT) (I) has two intrinsic chromophores: the phenol ring of Tyr2 and the Cys1-Cys6 disulfide bridge. Their emission and absorption characteristics indicate that tyrosyl fluorescence is attenuated by fluorescence-energy transfer to the disulfide bridge what can be used to calc. an av. inter-chromophore distance in the cyclic-hexapeptide fragment of oxytocin. [CONT.]

- ✓ Condensed
- ✓ Compelling
- ✓ Focused
- ✓ Reliable
- ✓ Integrated

Visualizations Capture Attention



- ✓ Condensed
- ✓ Compelling
- ✓ Focused

And sometimes keep attention too

Quantum Computing top assignees

Filtered by Priority Date: Dates/Extract Years up to: ‹ 2006 ›



	Title	Database	Common Family	Patent Family: Patent	Kind	Date	Patent Assignee
1	**USE OF SELECTIVE HYDROGEN ETCHING TECHNIQUE FOR BUILDING TOPOLOGICAL QUBITS** *1a Innov*	**1a Innov** | *link* **1b FAMPAT** | *link*	WO 201910090	WO 201910090 US 20190013457	A1 A1	2019-01-10 2019-01-10	MICROSOFT TECHNOLOGY LICENSING *1b FAMPAT*
2	**Quantum information control method for performing quantum logic gates in computing system, involves applying two-qubit quantum logic gate to pair of qubits in quantum processor by communicating control signal to control line** *2a Innov*	**2a Innov** | *link* **2b Innov** | *link* **2c FAMPAT** | *link*	WO 2018236922	WO 2018236922	A1	2018-12-27	RIGETTI *MPAT*
3	**Method for integrating resources of classical computing and non-classical computing hybrid computing system, involves solving QUBO problem with quantum processor having sequence of quantum logic gates** *3a Innov*	**3a Innov** | *link* **3b Innov** | *link* **3c FAMPAT** | *link* **3d FAMPAT** | *link*	WO 2018119522			*3a Innov*	*3d FAMPAT*
4	**Method for generating quantum logic control sequence for quantum information processor, involves identifying quantum computation to be performed**	**4a Innov** | *link* **4b Innov** | *link* **4c FAMPAT** | *link*	WO 2018089792	WO 2018089792 US 20180232652	A1 A1	2018-05-17 2018-08-16	RIGETTI

- ✓ Condensed
- ✓ Compelling
- ✓ Focused
- ✓ Reliable
- ✓ Integrated

Tables work

https://www.unsw.edu.au/newsroom/news/2017/08/mathematical-mystery-of-ancient-clay-tablet-solved

Tables can integrate many sources

	Title	Database	Patent Family			Probable Assignee	FTO Family with Expiry						Sequence Locations				
			Patent	Kind	Date		Pub No.	Kind	Pub Date	State	Status	Est Expiry	Seq. ID #	% Identity	Length	Location	
1	**New bacteriophage comprises polynucleotide expressing RNA-directed DNA-binding polypeptide comprising nuclease module, and targeting module comprising guide RNA, for restricting growth of host cell, and for preparing antiseptic composition** *1e Innov*	**1a Patbase** | *link* **1b FAM** | *link* **1c GQP** | *link* **1d GQP** | *link* **1e Innov** | *link* **1f Innov** | *link*	WO 2015070193 US 2015132263 US 2015353901 *1a Patbase*	A1 A A	2015-05-14 2015-05-14 2015-12-10	RADIANT GENOMICS INC *1a Patbase*	WO 201570193 US 20150132263 US 20150353901 *1b FAM*	A1 A1 A1	2015-05-14 2015-05-14 2015-12-10	DEAD DEAD DEAD	LAPSED LAPSED LAPSED	2017-05-11 2016-10-11 2016-10-03	US20150132263-0002 US20150353901-0002	100.00 100.00	1368 1368	claim: 19; 20 claim: 19; 20	1c 1d
2	**RNA-GUIDED TRANSCRIPTIONAL REGULATION** *2 Patbase*	**2 Patbase** | *link* **2 FAM** | *link* **2 GQP** | *link* **2 GQP** | *link* **2 GQP** | *link* **2 GQP** | *link* **2 GQP** | *link* **2 Innov** | *link* **2 Innov** | *link* *2 FAM*	US 9267135 US 20140356959 US 10640789 US 20160237456 US 10767194 US 20200024618 US 20140356956 US 20200299732 *2 Patbase*	B2 A1 B2 A1 B2 A1 A1 A1	2016-02-23 2014-12-04 2020-05-05 2016-08-18 2020-09-08 2020-01-23 2014-12-04 2020-09-24	PRESIDENT AND FELLOWS OF HARVARD COLLEGE *2 Patbase*	US 9267135 US 20140356959 US 10640789 US 20160237456 US 10767194 US 20200024618 US 20140356956 US 20200299732 *2 FAM*	B2 A1 B2 A1 B2 A1 A1 A1	2016-02-23 2014-12-04 2020-05-05 2016-08-18 2020-09-08 2020-01-23 2014-12-04 2020-09-24	ALIVE ALIVE ALIVE ALIVE ALIVE ALIVE	GRANTED GRANTED GRANTED PENDING PENDING	2034-06-04 2034-06-04 2034-06-04 2034-06-04 2034-06-04 2034-06-04	US20140356959-0001 US9267135-0001 US20200024618-0001 US20160237456-0001 US20140356956-0001	100.00 100.00	1368 1368	probable probable disclosure (not found by automated parsing)	2 2
3	**LARGE GENE EXCISION AND INSERTION**	**3a Patbase** | *link* **3b FAM** | *link* **3c GQP** | *link* **3d GQP** | *link* **3e GQP** | *link* **3f GQP** | *link* **3g GQP** | *link* **3h GQP** | *link* **3i GQP** | *link* **3j GQP** | *link* **3k Innov** | *link*	US 20150140664 WO 2015077290 WO 2015077290 CA 2930828 AU 2014353100 KR 2016078502 EP 3071698 JP 2016537982 EP 3071698 HK 1229380 EP 3071698 EP 3604543	A1 A2 A3 A1 A1 A A2 A A4 A B1 A1	2015-05-21 2015-05-28 2015-08-06 2015-05-28 2016-06-02 2016-07-04 2016-09-28 2016-12-08 2017-06-28 2017-11-17 2019-09-04 2020-02-05	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	EP 3071698 EP 3071698 EP 3071698 EP 3604543 WO 201577290 WO 201577290 US 10787684 US 20150140664 JP 2016537982 JP 2020062033 DK 3071698T ES 2754498	B1 A2 A4 A1 A2 A3 B2 A1 A A T3 T3	2019-09-04 2016-09-28 2017-06-28 2020-02-05 2015-05-28 2015-08-06 2020-09-29 2015-05-21 2016-12-08 2020-04-23 2019-11-18 2020-04-17	ALIVE ALIVE ALIVE ALIVE ALIVE ALIVE	GRANTED PENDING GRANTED PENDING GRANTED GRANTED	2034-11-19 2034-11-19 2034-06-30 2034-11-19 2034-11-19 2034-11-19	JP2016537982-0001 US20150140664-0001 WO2015077290-0001	100.00 100.00 100.00	1368 1368 1368	probable disclosure (not found by automated parsing) probable disclosure (not found by automated parsing) probable disclosure (not found by automated parsing)	3c 3d 3e

✓ **Condensed**

✓ **Compelling**

✓ **Focused**

✓ **Reliable**

✓ **Integrated**

What condenses the condensers?

	Title	Database	Patent Family			Probable Assignee	FTO Family with Expiry						Sequence Locations			
			Patent	Kind	Date		Pub No.	Kind	Pub Date	State	Status	Est Expiry	Seq. ID #	% Identity	Length	Location
1a	COMPOSITIONS AND METHODS FOR TARGETED GENE DISRUPTION IN PROKARYOTES	PatBase	WO 2015070193	A1	2015-05-14	RADIANT GENOMICS IN										
			US 2015132263	A	2015-05-14											
			US 2015353901	A	2015-12-10											
1b	Compositions and methods for targeted gene disruption in prokaryotes	FAMPAT	WO 201570193	A1	2015-05-14	ZYMERGEN	WO 201570193	A1	2015-05-14	DEAD	LAPSED	2017-05-11				
			US 20150132263	A1	2015-05-14		US 20150132263	A1	2015-05-14	DEAD	LAPSED	2016-10-11				
			US 20150353901	A1	2015-12-10		US 20150353901	A1	2015-12-10	DEAD	LAPSED	2016-10-03				
1c	COMPOSITIONS AND METHODS FOR TARGETED GENE DISRUPTION IN PROKARYOTES	GQPAT Gold+ Proteins	US20150132263		20150514								US20150132263-0002	100.00	1368	claim: 19; 20
			US20150353901													
			WO2015070193													
1d	Compositions and Methods for Targeted Gene Disruption in Prokaryotes	GQPAT Gold+ Proteins	US20150353901		20151210								US20150353901-0002	100.00	1368	claim: 19; 20
			US20150132263													
			WO2015070193													
1e	New bacteriophage comprises polynucleotide expressing RNA-directed DNA-binding polypeptide comprising nuclease module, and targeting module comprising guide RNA, for restricting growth of host cell, and for preparing antiseptic composition	Derwent Innovation DWPI	US 20150353901	A1	2015-12-10											
1f	New bacteriophage comprising polynucleotide that expresses RNA-directed DNA-binding polypeptide and targeting module comprising guide RNA, used e.g. for treating autoimmune and inflammatory disease, and disease caused by bacterial infection	Derwent Innovation DWPI	US 20150132263	A1	2015-05-14											
			WO 2015070193	A1	2015-05-14											

Integrators- the Smart Data Integrator lets you select key data for each set of related records, based on your rules and selections.

Integrators (the Smart Data Integrator)

	Title	Database	Patent Family: Patent	Kind	Date	Probable Assignee	FTO Family with Expiry: Pub No.	Kind	Pub Date	State	Status	Est Expiry	Sequence Locations: Seq. ID #	% Identity	Length	Location	
1	New bacteriophage comprises polynucleotide expressing RNA-directed DNA-binding polypeptide comprising nuclease module, and targeting module comprising guide RNA, for restricting growth of host cell, and for preparing antiseptic composition *1e Innov*	1a Patbase | link 1b FAM | link 1c GQP | link 1d GQP | link 1e Innov | link 1f Innov | link	WO 2015070193 US 2015132263 US 2015353901	A1 A A	2015-05-14 2015-05-14 2015-12-10	RADIANT GENOMICS IN	WO 2015070193 US 2015132263 US 2015353901	A1 A A	2015-05-14 2015-05-14 2015-12-10	DEAD DEAD DEAD	LAPSED LAPSED LAPSED	2017-05-11 2016-10-11 2016-10-03	US20150132263-0002 US20150353901-0002	100.00 100.00	1368 1368	claim: 19; 20 claim: 19; 20	1c 1d
			1a Patbase			*1a Patbase*						*1b FAM*					
2	RNA-GUIDED TRANSCRIPTIONAL REGULATION New bacteriophage comprises polynucleotide expressing RNA-directed DNA-binding polypeptide comprising nuclease module, and targeting module comprising guide RNA, for restricting growth of host cell, and for preparing antiseptic composition *2 Patbase*	2 Patbase | link 2 FAM | link 2 GQP | link	US 9267135 US 20140356959 US 10640789 US 20160237456 US 10767194 US 20200024618 US 20140356956 US 20200299732	B2 A1 B2 A1 B2 A1 A1 A1	2016-02-23 2014-12-04 2020-05-05 2016-08-18 2020-09-08 2020-01-23 2014-12-04 2020-09-24	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	US 9267135 US 20140356959 US 10640789 US 20160237456 US 10767194 US 20200024618 US 20140356956 US 20200299732	B2 A1 B2 A1 B2 A1 A1 A1	2016-02-23 2014-12-04 2020-05-05 2016-08-18 2020-09-08 2020-01-23 2014-12-04 2020-09-24	ALIVE ALIVE ALIVE ALIVE	GRANTED GRANTED PENDING PENDING	2034-06-04 2034-06-04 2034-06-04 2034-06-04	US20140356959-0001 US9267135-0001 US20200024618-0001 US20160237456-0001 US20140356956-0001	100.00 100.00 100.00 100.00 100.00	1368 1368 1368 1368 1368	probable disclosure (not found by automated parsing) probable disclosure (not found by automated parsing) probable disclosure (not found by automated parsing) probable disclosure (not found by automated parsing) probable disclosure (not found by automated parsing)	2 2 2 2 2
			2 FAM			*2 Patbase*						*2 FAM*					
3	LARGE GENE EXCISION AND INSERTION	3a Patbase | link 3b FAM | link 3c GQP | link 3d GQP | link 3e GQP | link 3f GQP | link 3g GQP | link 3h GQP | link 3i GQP | link 3j GQP | link 3k Innov | link	US 20150140664 WO 2015077290 WO 2015077290 CA 2930828 AU 2014353100 KR 2016078502 EP 3071698 JP 2016537982 EP 3071698 HK 1229380 EP 3071698 EP 3604543	A1 A2 A3 A1 A1 A A2 A A4 A B1 A1	2015-05-21 2015-05-28 2015-08-06 2015-05-28 2016-06-02 2016-07-04 2016-09-28 2016-12-08 2017-06-28 2017-11-17 2019-09-04 2020-02-05	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	EP 3071698 EP 3071698 EP 3071698 EP 3604543 WO 201577290 WO 201577290 US 10787684 US 20150140664 JP 2016537982 JP 2020062033 DK 3071698T ES 2754498	B1 A2 A4 A1 A2 A3 B2 A1 A A T3 T3	2019-09-04 2016-09-28 2017-06-28 2020-02-05 2015-05-28 2015-08-06 2020-09-29 2015-05-21 2016-12-08 2020-04-23 2019-11-18 2020-04-17	ALIVE DEAD ALIVE ALIVE ALIVE ALIVE ALIVE	GRANTED PENDING LAPSED GRANTED PENDING PENDING GRANTED GRANTED	2034-11-19 2034-11-19 2017-05-19 2034-06-30 2034-11-19 2034-11-19 2034-11-19 2034-11-19	JP2016537982-0001 US20150140664-0001 WO2015077290-0001	100.00 100.00 100.00	1368 1368 1368	probable disclosure (not found by automated parsing) probable disclosure (not found by automated parsing) probable disclosure (not found by automated parsing)	3c 3d 3e

Create a summary that

US20150132263-0002	100.00	1368	claim: 19; 20
US20150353901-0002	100.00	1368	claim: 19; 20

information from all your sources.

Tables with Visuals - Structures

8	**1021701-88-1** Oxytocin, 9-L-valinamide-(CA INDEX NAME)	 Absolute stereochemistry shown	conopressin-T from mollusk venom reveals antagonist switch in vasopressin-like peptides *Reference 12*
9	**115951-25-2** Oxytocin, 4-(N,N-dimethyl-L-glutamine)-5-(N,N-dimethyl-L-asparagine)-(9CI) (CA INDEX NAME)	 Absolute stereochemistry shown	antioxytocic activity of oxytocin and vasopressin analogs *Reference 13* antioxytocic activity of oxytocin and vasopressin analogs *Reference 13* prepn. and liq. secondary ion mass spectrum of *Reference 17*

Tables with Visuals - Sequences

	Title	Database	Common Family	Sequence	Alignment
1	**DOUBLE-STRANDED OLIGONUCLEOTIDE AGENTS AND USES THEREOF** *1a Patbase*	**1a Patbase** | *link* **1b PatSnap** | *link* **1c GQP** | *link* **1d GQP** | *link* **1e GQP** | *link*	WO 2025021034	CCATGTACGCTCATTGTGGATGACGA TGTACGCTCATTGTGGATGACGA CCTTGTACGCTCATTGTGGATGACGA	Q: 1 UGUACUCUCAUUGUGGAUGACGA 23 +|+|| |+||++|+||+||||| S: 4 TGTACGCTCATTGTGGATGACGA 26 *1c GQP*
2	**COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF ANGIOTENSINOGEN (AGT) GENES** *2a Patbase*	**2a Patbase** | *link* **2b PatSnap** | *link* **2c GQP** | *link* **2d GQP** | *link* **2e GQP** | *link*	WO 2024187193	TGTACTCTCATTGTGGATGACGA GGTACTCTCATTGTGGATGACGA	Q: S: ✓ Condensed ✓ Compelling ✓ Focused ✓ Reliable ✓ Integrated *2c GQP*
3	**RIBAVIRIN ANALOG AND USE THEREOF AS EMBEDDING GROUP** *3a Patbase*	**3a Patbase** | *link* **3b PatSnap** | *link* **3c GQP** | *link* **3d GQP** | *link* **3e GQP** | *link*	WO 2023155909	TGTACTCTCATTGTGGATGACGA TGTACNCTCATTGTGGATGACGA	Q: 1 UGUACUCUCAUUGUGGAUGACGA 23 +|+||+|+||++|+||+||||| S: 1 TGTACTCTCATTGTGGATGACGA 23 *3c GQP*

Alternatively, Sequence Summary

	Title	Database	Common Family	Sequence Summary			
				Seq. ID	% Identity	Location	
1	**DOUBLE-STRANDED OLIGONUCLEOTIDE AGENTS AND USES THEREOF** *1a Patbase*	**1a Patbase** | *link* **1b PatSnap** | *link* **1c GQP** | *link* **1d GQP** | *link* **1e GQP** | *link*	WO 2025021034	WO2025021034-0118	95.65	TBD (information not in GQ-Pat)	1c
				WO2025021034-0176	95.65	TBD (information not in GQ-Pat)	1d
				WO2025021034-0114	95.65	TBD (information not in GQ-Pat)	1e
2	**COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF ANGIOTENSINOGEN (AGT) GENES** *2a Patbase*	**2a Patbase** | *link* **2b PatSnap** | *link* **2c GQP** | *link* **2d GQP** | *link* **2e GQP** | *link*	WO 2024187193	WO2024187193-0655	100.00	probable disclosure (not found by automated parsing)	2c
				WO2024187193-0522	95.65	probable disclosure (not found by automated parsing)	2d
				WO2024187193-0635	100.00	probable disclosure (not found by automated parsing)	2e
3	**RIBAVIRIN ANALOG AND USE THEREOF AS EMBEDDING GROUP**	**3a Patbase** | *link* **3b PatSnap** | *link* **3c GQP** | *link* **3d GQP** | *link* **3e GQP** | *link*	WO 2023155909	WO2023155909-0003	100.00	probable disclosure (not found by automated parsing)	3c
				WO2023155909-0004	95.65	claim: 13	3d
				WO2023155909-0006	95.65	claim: 14	3e

AI is excellent at Capturing Attention
But... can it keep it?





rez0
@rez0__

I saw a guy coding today.
No cursor.
No windsurf.
No chatgpt.
He just sat there. Typing code manually.
Like a psychopath.

AI -- how does it work?

- ✓ Condensed
- ❑ Compelling
- ❑ Focused
- ❑ Reliable
- ✓ Integrated

Thank you very much!

Come talk with us at the break in the exhibit hall

More information at:
bizint.com/IP